Group 1 - Dingdang Health (09886) saw a stock price increase of over 5%, reaching a rise of 6.82% to HKD 0.94, with a trading volume of HKD 5.2407 million [1] - Recently, Dingdang Health announced a partnership with Eli Lilly, expanding the availability of Tirzepatide injection (Mounjaro) to pharmacies in Guangzhou and Shenzhen, following its introduction in Beijing [1] - According to Tianfeng Securities, over 2.6 billion people globally were affected by overweight/obesity in 2020, indicating a growing weight loss market, with Eli Lilly being a leading company in this sector [1] Group 2 - Dingdang Health aims to leverage Eli Lilly's innovative drug products and health education capabilities, combined with its own extensive smart pharmacy network, end-to-end intelligent logistics system, and professional healthcare team, to provide a comprehensive health solution for overweight/obese and diabetic populations [1] - The collaboration is expected to enhance medication accessibility and health management levels for targeted demographics [1]

叮当健康表示，依托礼来卓越的创新药产品、专业的健康科普能力，以及叮当健康广泛的多功能智慧药 房网络、端到端智能仓配体系、专业医生药师服务团队、全生命周期健康管理体系，双方将共同为超 重/肥胖、糖尿病等人群带来一站式健康解决方案，提升用药可及性和健康管理水平。 消息面上，近日，叮当健康宣布与利来集团达成合作，继北京地区之后，叮当健康在广州、深圳的药房 正式上架替尔泊肽注射液(穆峰达)。天风证券研报称，2020年全球已有超过26亿人受到超重/肥胖影响， 减重市场持续扩容，礼来是减重领域的龙头企业之一。 智通财经APP获悉，叮当健康(09886)涨超5%，截至发稿，涨6.82%，报0.94港元，成交额524.07万港 元。 ...